US2006009514A1PendingUtilityA1

Method for treating obesity

56
Individually held — no corporate assignee on recordPriority: May 17, 2002Filed: Sep 7, 2005Published: Jan 12, 2006
Est. expiryMay 17, 2022(expired)· nominal 20-yr term from priority
Inventors:Kishore M. GaddeK. Ranga R. Krishnan
A61P 43/00A61P 9/12A61P 3/10A61P 3/06A61K 31/423A61K 31/7024A61K 31/357A61K 31/137A61P 3/04A61K 45/06A61K 31/35A61P 31/04A61K 31/255A61K 31/42
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Claims

exact text as granted — not AI-modified
1 - 17 . (canceled)  
     
     
         18 . A method of treating obesity in a mammal comprising administering to a mammal in need of such treatment at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant wherein said anticonvulsant is of the formula (I):  
       
         
           
           
               
               
           
         
       
       wherein X is CH 2  or oxygen, 
 R 1  is hydrogen or alkyl, R 2 , R 3 , R 4  and R 5  are independently hydrogen or lower alkyl, and when X is CH 2 , R 4  and R 5  can be alkene groups joined to form a benzene ring and when X is oxygen, R 2  and R 3  and/or R 4  and R 5  together can be a methylenedioxy group of the following formula (II):  
                     
 wherein  
 R 6  and R 7  are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.  
 
     
     
         19 . The method of  claim 18  wherein R 1  is hydrogen or a C 1 -C 4  alkyl, straight and branched chain, and R 2 , R 3 , R 4 , R 5 , R 6  and R 7  are a C 1 -C 3  alkyl, straight or branched chain.  
     
     
         20 . The method of  claim 18  wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.  
     
     
         21 . The method of  claim 18 , wherein said anticonvulsant is topiramate.  
     
     
         22 . The method of  claim 18 , wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered separately.  
     
     
         23 . The method of  claim 18 , wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered concurrently.  
     
     
         24 . A method of reducing the risk of hypertension, diabetes or dyslipidaemia in a mammal comprising administering to a mammal in need of such reduction at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant according to formula (I) in amounts such that said reduction is effected, where formula (I) is:  
       
         
           
           
               
               
           
         
       
       wherein X is CH 2  or oxygen, 
 R 1  is hydrogen or alkyl,  
 R 2 , R 3 , R 4  and R 5  are independently hydrogen or lower alkyl, and when X is CH 2 , R 4  and R 5  can be alkene groups joined to form a benzene ring and when X is oxygen, R 2  and R 3  and/or R 4  and R 5  together can be a methylenedioxy group of the following formula (II):  
                     
 wherein  
 R 6  and R 7  are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.  
 
     
     
         25 . A composition comprising at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant of formula (1):  
       
         
           
           
               
               
           
         
       
       wherein X is CH 2  or oxygen, 
 R 1  is hydrogen or alkyl,  
 R 2 , R 3 , R 4  and R 5  are independently hydrogen or lower alkyl, and when X is CH 2 , R 4  and R 5  can be alkene groups joined to form a benzene ring and when X is oxygen, R 2  and R 3  and/or R 4  and R 5  together can be a methylenedioxy group of the following formula (II):  
                     
 wherein  
 R 6  and R 7  are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.  
 
     
     
         26 . The composition of  claim 25 , wherein said anticonvulsant is topiramate.  
     
     
         27 . The composition of  claim 25 , wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.  
     
     
         28 . The composition of  claim 25 , wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion and said anticonvulsant is topiramate.  
     
     
         29 . The composition of  claim 25 , wherein said compound is in dosage unit form.  
     
     
         30 . The composition of  claim 25 , wherein said composition is in the form of a tablet or capsule.

Join the waitlist — get patent alerts

Track US2006009514A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.